Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.
Sign Up to like & getrecommendations! Published in 2021 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2020.115299
Abstract: Cefazolin susceptibility of urine isolates of Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis predicts susceptibility to oral cephalosporins, but cefazolin-resistant isolates may be susceptible to oral third-generation cephalosporins. Among 194 urine isolates, we found >95%… read more here.
Keywords: susceptibility; testing oral; third generation; surrogate testing ... See more keywords
Evidence of Failure of Oral Third-Generation Cephalosporin Treatment for Shigella sonnei Infection.
Sign Up to like & getrecommendations! Published in 2020 at "Open forum infectious diseases"
DOI: 10.1093/ofid/ofaa113
Abstract: In 2017, state health departments notified the Centers for Disease Control and Prevention about 4 patients with shigellosis who experienced persistent illness after treatment with oral third-generation cephalosporins. Given increasing antibiotic resistance among Shigella, these… read more here.
Keywords: failure oral; treatment; third generation; evidence failure ... See more keywords
Reduction strategies for inpatient oral third-generation cephalosporins at a cancer center: An interrupted time-series analysis
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0281518
Abstract: Oral third-generation cephalosporins (3GCs) are not recommended for use owing to their low bioavailability and the risk of emergence of resistant microorganisms with overuse. A standardized and effective method for reducing their use is lacking.… read more here.
Keywords: time; cancer; third generation; phase ... See more keywords